Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rolapitant
Drug ID BADD_D01963
Description Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration. Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and late-phase CINV during the first 120 hours post-chemotherapy.
Indications and Usage This drug is indicated in adults in combination with other antiemetics for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy.
Marketing Status approved; investigational
ATC Code A04AD14
DrugBank ID DB09291
KEGG ID D10742
MeSH ID C578834
PubChem ID 10311306
TTD Drug ID D0CF0Y
NDC Product Code 70720-101; 47848-053
UNII NLE429IZUC
Synonyms rolapitant | (5S,8S)-8-(((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4.5)decan-2-one | Varubi | SCH 619734 | 8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one
Chemical Information
Molecular Formula C25H26F6N2O2
CAS Registry Number 552292-08-7
SMILES CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OCC2(CCC3(CCC(=O)N3)CN2)C4=CC=CC=C4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.0020.000162%
Abdominal pain upper07.01.05.0030.000081%
Anaemia01.03.02.0010.000081%
Anxiety19.06.02.0020.000121%
Back pain15.03.04.0050.000638%
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.000081%Not Available
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.000461%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.000162%Not Available
Constipation07.02.02.0010.000081%
Cough22.02.03.0010.000202%
Death08.04.01.0010.002464%
Dehydration14.05.05.0010.000081%
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.000121%
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.0040.000703%
Erythema23.03.06.0010.000081%Not Available
Feeling hot08.01.09.0090.000323%Not Available
Flushing23.06.05.003; 08.01.03.025; 24.03.01.0020.001042%
Hiccups22.12.01.001; 07.01.06.009--
Hyperhidrosis23.02.03.004; 08.01.03.0280.000121%
Hypersensitivity10.01.03.0030.000081%
Hypertension24.08.02.0010.000121%
Hypokalaemia14.05.03.0020.000081%
Leukopenia01.02.02.0010.000081%Not Available
Loss of consciousness17.02.04.0040.000081%Not Available
Malaise08.01.01.0030.000259%
Micturition urgency20.02.02.0060.000081%
Muscle spasms15.05.03.0040.000081%
Nausea07.01.07.0010.000558%
Neutropenia01.02.03.0040.000081%Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages